HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Financial disclosure in oncology leaves ‘room for standardization’
• Should there be more focus on the financial relationship itself rather than its disclosure?
• NCCN’s off-label cancer treatment recommendations ‘constitute a problem’
• Oxygen: A ‘Nobel’ gas Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Treating the patient throughout the surgical process using evidence-based practice Lisa Parks, MS, APRN-CNP, ANP-BC
• Vincristine shortage underscores vulnerability of ‘fragile market’ for crucial treatments
• CAR T-cell therapy has some patients crowdfunding to cover costs
• AACR Cancer Progress Report: Past federal investments in NIH spurring breakthroughs in care
• Study suggests NCCN off-label recommendations valid based on available evidence
• Access to care among ‘critical priorities’ for American Cancer Society’s new chief medical, scientific officer
• Biomarkers could help identify children with cancer at risk for cognitive impairments
• Clinical trial participation studies show possible survival benefit, misconceptions of patient concerns
• African Americans, Hispanics less likely than whites to use hospice for pancreatic cancer
• Atezolizumab extends OS for PD-L1-selected patients with non-small cell lung cancer
• Nivolumab extends OS in advanced esophageal squamous cell carcinoma
• Immunotherapy-chemotherapy combination may reduce recurrence of triple-negative breast cancer
• Addition of veliparib to platinum chemotherapy extends PFS in BRCA-mutated breast cancer
• Atezolizumab extends PFS in metastatic urothelial cancer
• Apalutamide improves OS in nonmetastatic, castration-resistant prostate cancer
• Targeted therapy shows benefit in advanced cholangiocarcinoma
• Triplet therapy improves outcomes in BRAF V600E-mutant metastatic colorectal cancer
• Veliparib regimen extends PFS in newly diagnosed high-grade serous ovarian carcinoma
• Addition of olaparib to maintenance bevacizumab significantly improves PFS in ovarian cancer
• Addition of M6620 to gemcitabine prolongs PFS in platinum-resistant ovarian cancer
• Nivolumab-ipilimumab combination confers durable OS, PFS benefit in metastatic melanoma
• Speaker: Rationale exists to test CAR T-cell therapy in KRAS-mutated lung cancer
• First-line durvalumab plus chemotherapy improves OS in extensive-stage small cell lung cancer
• Video-assisted thoracic surgery linked to fewer complications in early lung cancer
• Tumor mutational burden an ineffective biomarker for response to pembrolizumab plus chemotherapy
• Survey reveals ‘suboptimal awareness’ of lung cancer molecular testing guidelines
• IASLC: All physicians should screen patients with cancer for tobacco use
• Drug costs, prior authorizations create barriers to timely cancer care
• Gilteritinib new standard of care for relapsed, refractory FLT3-mutated acute myeloid leukemia
• Ibrutinib plus venetoclax safely induces remission in relapsed, refractory chronic lymphocytic leukemia
• Clinically indicated ibrutinib interruptions do not limit long-term benefit in CLL
• Symptom burden a key component of disease control assessment in polycythemia vera
• Daratumumab regimen reduces risk for progression, death in newly diagnosed multiple myeloma
• OS rate for Hodgkin lymphoma remains high with PET response-adapted therapy
• Treatment for Hodgkin lymphoma during pregnancy appears safe
• Triplet therapy active in diffuse large B-cell lymphoma
• CD19-specific CAR T-cell therapy feasible for aggressive non-Hodgkin lymphoma
• Concizumab effective, safe for certain patients with hemophilia
• Transfusion timing, volume do not affect mortality among African children with severe anemia
• Greater cardiorespiratory fitness may reduce risk for venous thromboembolism
• Birth defects linked to increased risk for childhood cancer
• Foreign-born women less likely to have had a mammogram
• Molecular analysis may aid in tailoring treatment for certain patients with colorectal cancer
• Nivolumab with higher ipilimumab dose shows promising efficacy for bladder cancer
• Nivolumab-bevacizumab combination safe, active in relapsed ovarian cancer
• Adjuvant whole-brain radiotherapy ‘should not be recommended’ for certain patients with melanoma brain metastases
• Aggressive radiotherapy dose de-escalation confers benefits in HPV-associated oropharyngeal squamous cell carcinoma
• High-deductible health plans linked to delayed, forgone care among cancer survivors
• FDA grants priority review to zanubrutinib for relapsed/refractory mantle cell lymphoma
• FDA grants fast track designation to navicixizumab for pretreated ovarian cancer
• FDA grants orphan drug designation to Imfinzi for small cell lung cancer
• FDA grants breakthrough therapy designation to Calquence for chronic lymphocytic leukemia
• FDA approves Xarelto to prevent blood clots in acutely ill hospitalized patients
• FDA grants priority review to Xtandi for metastatic hormone-sensitive prostate cancer
• FDA approves Ruxience, biosimilar to Rituxan, for blood cancers, autoimmune conditions
• FDA approves pexidartinib, first therapy for tenosynovial giant cell tumor
• FDA awards $15 million to fund trials of treatments for rare diseases
• Childhood leukemia survivors may be at higher risk for infections
• Cancer researchers receive Lasker-DeBakey Clinical Medical Research Award
• Society honors Helen F. Graham Cancer Center medical director
• Cleveland Clinic appoints hematology/medical oncology department chair
• The Leukemia & Lymphoma Society awards $13.8 million for research into pediatric blood cancers
• The Wistar Institute researcher receives NIH New Innovator Award
• Ohio State cancer center appoints hematology division director
• Cancer Research Institute honors UCLA scientist for basic, tumor immunology discoveries
• Researchers share Nobel Prize for discoveries that may improve treatment of cancer, anemia